NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of SCYNEXIS, Inc. (NASDAQ:SCYX). On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration ("FDA") has placed a hold on clinical trials for the intravenous formulation of the Company’s lead product candidate SCY-078 “until the FDA completes a review of all available pre-clinical and clinical data.” SCYNEXIS advised investors that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.” Following this news, shares of SCYNEXIS were down more than 16% on intraday trading on March 3, 2017. To obtain additional information, go to:

http://zlk.9nl.com/scynexis-scyx

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Eduard Korsinsky, Esq.

30 Broad Street - 24th Floor

New York, NY 10004

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170303005707/en/